Danielle Flieler

Regulations under the Food and Drugs Act, including the Medical Devices Regulation, with respect to the approval of medical technologies North American Free Trade Agreement (NAFTA), with respect to provisions relating to medical devices and technologies Federal science & technology strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry Federal life sciences strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, antimicrobial resistance, and diagnostic testing. Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes. Federal initiatives with respect to the Canadian Life Sciences strategy and intergovernmental policy, funding, legislative, and guideline changes. Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry, and economic development and promotion for the life sciences sector Federal budget with respect to science and technology in the healthcare sector, specifically with respect to medical technology and device innovation and adoption, support and delivery new models of care, equitable healthcare access, and women’s health. Federal budget with respect to public sector investments in long-term care and home care. Discuss policies around anti-microbial resistance, infection prevention and medication errors

Discussions on the restructuring of the Canadian Preventative Health Task Force Regulations and guidelines affecting women's health like breast cancer screening, access to innovative technology and precision medicine. Communicating with government to increase investments in health research

Discussion on the use of AI/digital health and how that can help improve the profession and more efficient access to care for patients. Discussion on the health human resource issues facing dermatologists such as shortages, wait times and access to care for patients.

Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements. Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines. Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors. Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada. Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation. Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development. Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines. Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace. Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs. Engage with government to strengthen the Priority Review of Drug Submissions process. Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine. Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.

Supporting engagement on the value in curing type one diabetes across Canada by seeking funding for increased and innovative research.

Our key priorities focus on addressing the chronic underfunding of community mental health organizations, advocating for long-term, sustainable funding models to ensure their full integration into the health care system, and increasing visibility and awareness of their critical role within government.

Continued support for life sciences funding and the emerging area of stem cell and regenerative medicine research. Lobbying is about building awareness about the field and the strength of talent that works within the field.